Medical Research Council Centre for Inflammation Research and Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Stem Cells Dev. 2010 Feb;19(2):155-62. doi: 10.1089/scd.2009.0412.
Liver resection has been associated with significant morbidity and mortality due to hepatic dysfunction or hepatic failure in the postoperative period. Autologous bone marrow stem cell (BMSC) therapy may offer the potential to enhance hepatic regeneration in this setting, perhaps increasing the safety of the procedure. Preclinical models and initial translational studies have suggested that autologous BMSC administration can facilitate hepatic regeneration following both acute and chronic liver disease. While translational studies have begun in chronic hepatic disease, translation to hepatic surgical indications has been limited. This review explores the practical barriers currently restricting the delivery of autologous stem cell therapies to enhance hepatic regeneration following liver resection including selection of cell type, cell isolation, therapy delivery, trial design, and assessment of efficacy.
肝切除术由于术后肝功能或肝功能衰竭而导致发病率和死亡率显著增加。自体骨髓干细胞（BMSC）治疗可能有潜力增强这种情况下的肝再生，从而可能提高手术的安全性。临床前模型和初步转化研究表明，自体 BMSC 给药可以促进急性和慢性肝病后的肝再生。虽然在慢性肝病中已经开始了转化研究，但向肝外科适应证的转化受到限制。本综述探讨了目前限制自体干细胞疗法用于增强肝切除术后肝再生的实际障碍，包括细胞类型选择、细胞分离、治疗传递、试验设计和疗效评估。
